| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Urology, College of Physicians and Surgeons of Columbia University, New York, New York 10032 [A. J. R., H. P., M-W. C., J. S. S., R. B.], and Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan 48109 [M. L. D.]
Normal (nonneoplastic) human prostatic secretory epithelial cells do not express the bcl-2 protein. However, a recent immunohistochemical survey of neoplastic human prostate tissues showed that a fraction of primary untreated prostate adenocarcinoma cells expressed this apoptosis-suppressing oncoprotein at significant levels (Colombel et al., Am. J. Pathol., 143: 390–400, 1993). Additionally, a number of hormone-refractory prostatic adenocarcinomas obtained from hormonally-treated patients (subsequent to surgical or drug castration therapy) were examined and were found to be uniform in their elevated expression of bcl-2 oncoprotein. The results of this preliminary survey imply that bcl-2 expression distinguishes a subgroup of primary human prostate cancers and that the expression of this protein might be a factor enabling prostate cancer cells to survive in an androgen-deprived environment. The current study was undertaken to determine the degree to which overexpression of bcl-2 can protect human prostate cancer cells from apoptotic stimuli in vitro and in vivo. Human prostate cancer cells (LNCaP) were transfected with a neomycin-selectable eucaryotic expression vector containing cDNA encoding human bcl-2. Transfected clonal variants that express bcl-2 protein (LNCaP/bcl-2) were unaltered with regard to their basal growth rate in 10% serum-containing medium, or with regard to their expression of the differentiated human prostate cell gene products prostate-specific antigen or androgen receptor protein. The bcl-2-transfected clones were altered, however, with regard to their growth rate in charcoal-stripped serum lacking dihydrotestosterone. Additionally, in contrast to the parental or control-transfected cell lines, LNCaP/bcl-2 cells were highly resistant to a variety of apoptotic stimuli in vitro including serum starvation and 10 nM phorbol ester (phorbol 12-myristate 13-acetate) supplementation of the medium. Lastly, the overexpression of bcl-2 by these prostate cancer cells altered their tumorigenic potential in a nude mouse assay. s.c. injections of 106 LNCaP/bcl-2 cells into male nude mice resulted in earlier and larger tumor formation compared to an equivalent injection of parental or control-transfected LNCaP cells. When these variant cell lines were injected into castrated male nude mice, only the LNCaP/bcl-2-transformed cells gave rise to tumors. Moreover, LNCaP/bcl-2 tumors grown in intact male nude mice were refractory to the growth-inhibiting effects of castration demonstrated by parental LNCaP cells. Data obtained in this study demonstrate that the bcl-2 oncoprotein can protect prostate cancer cells from apoptotic stimuli in vitro and suggest that such protection correlates with the ability to form hormone-refractory prostate tumors in vivo.
1 This work was supported by United States Public Health Service Grants NIH-CA58089 and NIH-CA47848, as well as grants from the CaPCure Foundation and the Koch Foundation. M-W. C. is a research fellow of the American Foundation for Urological Disease.
2 To whom requests for reprints should be addressed, at Department of Urology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032.
Received 4/ 4/95. Accepted 8/ 2/95.
This article has been cited by other articles:
|
|
 |
|
  J. Concato, D. Jain, E. Uchio, H. Risch, W. W. Li, and C. K. Wells Molecular Markers and Death From Prostate Cancer Ann Intern Med, May 5, 2009; 150(9): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Martin, A. Miller, L. Emad, M. Rahmani, T. Walker, C. Mitchell, M. P. Hagan, M. A. Park, A. Yacoub, P. B. Fisher, et al. Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation Mol. Pharmacol., September 1, 2008; 74(3): 807 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhai, C. Jin, C.-w. Shiau, S. Kitada, A. C. Satterthwait, and J. C. Reed Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins Mol. Cancer Ther., June 1, 2008; 7(6): 1639 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Dinnen, L. Drew, D. P. Petrylak, Y. Mao, N. Cassai, J. Szmulewicz, P. Brandt-Rauf, and R. L. Fine Activation of Targeted Necrosis by a p53 Peptide: A NOVEL DEATH PATHWAY THAT CIRCUMVENTS APOPTOTIC RESISTANCE J. Biol. Chem., September 14, 2007; 282(37): 26675 - 26686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baritaki, S. Huerta-Yepez, T. Sakai, D. A. Spandidos, and B. Bonavida Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 Mol. Cancer Ther., April 1, 2007; 6(4): 1387 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-R. Yuan, R. Wang, J. Solomon, X. Luo, H. Sun, L. Zhang, and Y. Shi Identification and Characterization of Survival-Related Gene, a Novel Cell Survival Gene Controlling Apoptosis and Tumorigenesis Cancer Res., December 1, 2005; 65(23): 10716 - 10724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhu, L. Xiong, B. Yu, and J. Wu Apoptosis Induced by a New Member of Saponin Family Is Mediated through Caspase-8-Dependent Cleavage of Bcl-2 Mol. Pharmacol., December 1, 2005; 68(6): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Pienta and D. C. Smith Advances in Prostate Cancer Chemotherapy: A New Era Begins CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yang, M.-W. Chen, S. Terry, F. Vacherot, D. K. Chopin, D. L. Bemis, J. Kitajewski, M. C. Benson, Y. Guo, and R. Buttyan A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer Cells Cancer Res., June 15, 2005; 65(12): 5263 - 5271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Tolcher, K. Chi, J. Kuhn, M. Gleave, A. Patnaik, C. Takimoto, G. Schwartz, I. Thompson, K. Berg, S. D'Aloisio, et al. A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3854 - 3861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Syrovets, J. E. Gschwend, B. Buchele, Y. Laumonnier, W. Zugmaier, F. Genze, and T. Simmet Inhibition of I{kappa}B Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo J. Biol. Chem., February 18, 2005; 280(7): 6170 - 6180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, M. E. Gleave, I. Hara, M. Muramaki, and H. Miyake Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model Mol. Cancer Ther., February 1, 2005; 4(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lai, L. Benimetskaya, A. Khvorova, S. Wu, E. Hua, P. Miller, and C.A. Stein Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells Mol. Cancer Ther., February 1, 2005; 4(2): 305 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Unni, S. Sun, B. Nan, M. J. McPhaul, B. Cheskis, M. A. Mancini, and M. Marcelli Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence Cancer Res., October 1, 2004; 64(19): 7156 - 7168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rocchi, A. So, S. Kojima, M. Signaevsky, E. Beraldi, L. Fazli, A. Hurtado-coll, K. Yamanaka, and M. Gleave Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer Cancer Res., September 15, 2004; 64(18): 6595 - 6602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al. A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bemis, J. L. Capodice, M. Desai, R. Buttyan, and A. E. Katz A Concentrated Aglycone Isoflavone Preparation (GCP) That Demonstrates Potent Anti-Prostate Cancer Activity In vitro and In vivo Clin. Cancer Res., August 1, 2004; 10(15): 5282 - 5292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lemonnier, Y. Shuba, A. Crepin, M. Roudbaraki, C. Slomianny, B. Mauroy, B. Nilius, N. Prevarskaya, and R. Skryma Bcl-2-Dependent Modulation of Swelling-Activated Cl- Current and ClC-3 Expression in Human Prostate Cancer Epithelial Cells Cancer Res., July 15, 2004; 64(14): 4841 - 4848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Lee and C. Chang Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4043 - 4054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Yang, H.-P. Lin, C.-S. Chen, Y.-T. Yang, P.-H. Tseng, V. M. Rangnekar, and C.-S. Chen Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt Pathway in Prostate Cancer Cells J. Biol. Chem., July 3, 2003; 278(28): 25872 - 25878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Cheema, S. K. Mishra, V. M. Rangnekar, A. M. Tari, R. Kumar, and G. Lopez-Berestein Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter J. Biol. Chem., May 23, 2003; 278(22): 19995 - 20005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Nesslinger, X.-B. Shi, and R. W. deVere White Androgen-independent Growth of LNCaP Prostate Cancer Cells Is Mediated by Gain-of-Function Mutant p53 Cancer Res., May 1, 2003; 63(9): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. de la Taille, M. A. Rubin, M.-W. Chen, F. Vacherot, S. G.-D. de Medina, M. Burchardt, R. Buttyan, and D. Chopin {beta}-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells Clin. Cancer Res., May 1, 2003; 9(5): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Drew, R. L. Fine, T. N. Do, G. P. Douglas, and D. P. Petrylak The Novel Antimicrotubule Agent Cryptophycin 52 (LY355703) Induces Apoptosis via Multiple Pathways in Human Prostate Cancer Cells Clin. Cancer Res., December 1, 2002; 8(12): 3922 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Banerjee, S. Banerjee, and T. R. Brown Bcl-2 Protein Expression Correlates with Cell Survival and Androgen Independence in Rat Prostatic Lobes Endocrinology, May 1, 2002; 143(5): 1825 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vilenchik, A. J. Raffo, L. Benimetskaya, D. Shames, and C. A. Stein Antisense RNA Down-Regulation of bcl-xL Expression in Prostate Cancer Cells Leads to Diminished Rates of Cellular Proliferation and Resistance to Cytotoxic Chemotherapeutic Agents Cancer Res., April 1, 2002; 62(7): 2175 - 2183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Morris, W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al. Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer Clin. Cancer Res., March 1, 2002; 8(3): 679 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Garcia-Bermejo, F. C. Leskow, T. Fujii, Q. Wang, P. M. Blumberg, M. Ohba, T. Kuroki, K.-C. Han, J. Lee, V. E. Marquez, et al. Diacylglycerol (DAG)-lactones, a New Class of Protein Kinase C (PKC) Agonists, Induce Apoptosis in LNCaP Prostate Cancer Cells by Selective Activation of PKCalpha J. Biol. Chem., January 4, 2002; 277(1): 645 - 655. [Abstract] [Full Text]
|
|
|
|
|
|
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Grossmann, H. Huang, and D. J. Tindall Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1687 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, J. C. Cheville, Y. Pan, P. C. Roche, L. J. Schmidt, and D. J. Tindall PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression J. Biol. Chem., October 12, 2001; 276(42): 38830 - 38836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zellweger, H. Miyake, S. Cooper, K. Chi, B. S. Conklin, B. P. Monia, and M. E. Gleave Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 934 - 940. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. R. Sparrow and B. Cai Blue Light-Induced Apoptosis of A2E-Containing RPE: Involvement of Caspase-3 and Protection by Bcl-2 Invest. Ophthalmol. Vis. Sci., May 1, 2001; 42(6): 1356 - 1362. [Abstract] [Full Text]
|
|
|
|
|
|
G. Kulik, J. P. Carson, T. Vomastek, K. Overman, B. D. Gooch, S. Srinivasula, E. Alnemri, G. Nunez, and M. J. Weber Tumor Necrosis Factor {{alpha}} Induces BID Cleavage and Bypasses Antiapoptotic Signals in Prostate Cancer LNCaP Cells Cancer Res., March 1, 2001; 61(6): 2713 - 2719. [Abstract] [Full Text]
|
|
|
|
|
|
X. Li, M. Marani, J. Yu, B. Nan, J. A. Roth, S. Kagawa, B. Fang, L. Denner, and M. Marcelli Adenovirus-mediated Bax Overexpression for the Induction of Therapeutic Apoptosis in Prostate Cancer Cancer Res., January 1, 2001; 61(1): 186 - 191. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Van Coppenolle, C. Slomianny, F. Carpentier, X. Le Bourhis, A. Ahidouch, D. Croix, G. Legrand, E. Dewailly, S. Fournier, H. Cousse, et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E120 - E129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lebedeva, R. Rando, J. Ojwang, P. Cossum, and C. A. Stein Bcl-xL in Prostate Cancer Cells: Effects of Overexpression and Down-Regulation on Chemosensitivity Cancer Res., November 1, 2000; 60(21): 6052 - 6060. [Abstract] [Full Text]
|
|
|
|
|
|
U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright, and M. Hussain Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma Clin. Cancer Res., November 1, 2000; 6(11): 4205 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]
|
|
|
|
 |
|
 R. Skryma, P. Mariot, X. Le Bourhis, F. Van Coppenolle, Y. Shuba, F. V. Abeele, G. Legrand, S. Humez, B. Boilly, and N. Prevarskaya Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis J. Physiol., August 15, 2000; 527(1): 71 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fujii, M. L. Garcia-Bermejo, J. L. Bernabo, J. Caamano, M. Ohba, T. Kuroki, L. Li, S. H. Yuspa, and M. G. Kazanietz Involvement of Protein Kinase C delta (PKCdelta ) in Phorbol Ester-induced Apoptosis in LNCaP Prostate Cancer Cells. LACK OF PROTEOLYTIC CLEAVAGE OF PKCdelta J. Biol. Chem., March 10, 2000; 275(11): 7574 - 7582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Navone, M. d. C. Rodriguez-Vargas, W. F. Benedict, P. Troncoso, T. J. McDonnell, J.-H. Zhou, R. Luthra, and C. J. Logothetis TabBO: A Model Reflecting Common Molecular Features of Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1190 - 1197. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z Kolár, P G Murray, K Scott, A Harrison, B Vojtesek, and J Dusek Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer Mol. Pathol., February 1, 2000; 53(1): 15 - 18. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miayake, A. Tolcher, and M. E. Gleave Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Blutt, T. J. McDonnell, T. C. Polek, and N. L. Weigel Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2 Endocrinology, January 1, 2000; 141(1): 10 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lu, S. Y. Tsai, and M.-J. Tsai Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI Cells Endocrinology, November 1, 1999; 140(11): 5054 - 5059. [Abstract] [Full Text]
|
|
|
|
|
|
A. de la Taille, M.-W. Chen, M. Burchardt, D. K. Chopin, and R. Buttyan Apoptotic Conversion: Evidence for Exchange of Genetic Information between Prostate Cancer Cells Mediated by Apoptosis Cancer Res., November 1, 1999; 59(21): 5461 - 5463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bubendorf, M. Kolmer, J. Kononen, P. Koivisto, S. Mousses, Y. Chen, E. Mahlamaki, P. Schraml, H. Moch, N. Willi, et al. Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays J Natl Cancer Inst, October 20, 1999; 91(20): 1758 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, and J. Goldie Progression to Androgen Independence Is Delayed by Adjuvant Treatment with Antisense Bcl-2 Oligodeoxynucleotides after Castration in the LNCaP Prostate Tumor Model Clin. Cancer Res., October 1, 1999; 5(10): 2891 - 2898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, A. Tolcher, and M. E. Gleave Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model Cancer Res., August 1, 1999; 59(16): 4030 - 4034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lin, R. M. Adam, E. Santiestevan, and M. R. Freeman The Phosphatidylinositol 3'-kinase Pathway Is a Dominant Growth Factor-activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells Cancer Res., June 1, 1999; 59(12): 2891 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pasquali, V. Rossi, D. Prezioso, V. Gentile, V. Colantuoni, T. Lotti, A. Bellastella, and A. A. Sinisi Changes in Tissue Transglutaminase Activity and Expression during Retinoic Acid-Induced Growth Arrest and Apoptosis in Primary Cultures of Human Epithelial Prostate Cells J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1463 - 1469. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Lu, M. Liu, D. E. Epner, S. Y. Tsai, and M.-J. Tsai Androgen Regulation of the Cyclin-Dependent Kinase Inhibitor p21 Gene through an Androgen Response Element in the Proximal Promoter Mol. Endocrinol., March 1, 1999; 13(3): 376 - 384. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Guo and N. Kyprianou Restoration of Transforming Growth Factor {beta} Signaling Pathway in Human Prostate Cancer Cells Suppresses Tumorigenicity via Induction of Caspase-1-mediated Apoptosis Cancer Res., March 1, 1999; 59(6): 1366 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lapointe, A. Fournier, V. Richard, and C. Labrie Androgens Down-Regulate bcl-2 Protooncogene Expression in ZR-75-1 Human Breast Cancer Cells Endocrinology, January 1, 1999; 140(1): 416 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
M. Marcelli, G. R. Cunningham, M. Walkup, Z. He, L. Sturgis, C. Kagan, R. Mannucci, I. Nicoletti, B. Teng, and L. Denner Signaling Pathway Activated during Apoptosis of the Prostate Cancer Cell Line LNCaP: Overexpression of Caspase-7 as a New Gene Therapy Strategy for Prostate Cancer Cancer Res., January 1, 1999; 59(2): 382 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Day, R. G. Foster, K. C. Day, X. Zhao, P. Humphrey, P. Swanson, A. A. Postigo, S. H. Zhang, and D. C. Dean Cell Anchorage Regulates Apoptosis through the Retinoblastoma Tumor Suppressor/E2F Pathway J. Biol. Chem., March 28, 1997; 272(13): 8125 - 8128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kyle, L. Neckers, C. Takimoto, G. Curt, and R. Bergan Genistein-Induced Apoptosis of Prostate Cancer Cells is Preceded by a Specific Decrease in Focal Adhesion Kinase Activity Mol. Pharmacol., February 1, 1997; 51(2): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nesterov, X. Lu, M. Johnson, G. J. Miller, Y. Ivashchenko, and A. S. Kraft Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis J. Biol. Chem., March 30, 2001; 276(14): 10767 - 10774. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
